Transgenic Animals: Creation, Applications, and Ethical Considerations
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- Transgenic animals are created by introducing foreign DNA (transgenes) into the germline, enabling heritable genetic modifications, distinct from knockout or knock-in animals which involve endogenous gene inactivation or precise replacement.
- Historically, DNA microinjection into pronuclei and retroviral vector-mediated transfer were primary methods, with DNA microinjection being versatile for large constructs but having low efficiency and random integration, while retroviral vectors offer high integration efficiency but are limited by insert size and potential insertional mutagenesis.
- Embryonic stem (ES) cell-mediated gene targeting, particularly in mice, provides precise genetic modification via homologous recombination, allowing for targeted gene insertion or deletion, though its application is limited by the availability of germline-competent ES cells in other species.
- Transgenic animals serve critical roles in research, including elucidating gene function through overexpression or dominant-negative effects, modeling human diseases (e.g., Alzheimer's, Huntington's, cancer) by introducing disease-associated mutations, and acting as "bioreactors" for producing biopharmaceuticals like antithrombin III in milk.
- Advanced technologies like CRISPR/Cas9 have revolutionized transgenic animal production by enabling highly efficient, targeted gene editing with multiplexing capabilities and reduced timelines, facilitating precise modifications in a wider range of species and paving the way for base and prime editing applications.
- Ethical considerations, including animal welfare during procedures like superovulation and embryo transfer, and regulatory frameworks governing genetically modified organisms (GMOs), are paramount, with principles like the "3Rs" (Replacement, Reduction, Refinement) guiding responsible research practices.
Introduction to Transgenic Animals
Definition and Basic Concept
A transgenic animal is an animal whose genome has been deliberately modified through the introduction of foreign DNA sequences. The introduced genetic material, termed a transgene, is stably integrated into the animal's germline, meaning the modification is heritable and passed to subsequent generations. The transgene can originate from the same species, a different species, or be a synthetic construct designed in the laboratory. The key distinction is that the genetic change is intentional, stable, and transmitted through reproduction.
It is essential to distinguish transgenic animals from other genetically modified animals. A knockout animal has a specific endogenous gene inactivated or "knocked out" through targeted disruption. A knock-in animal has a specific gene replaced or inserted at a precise chromosomal location. While knockout and knock-in animals involve genetic modification, they do not necessarily involve the introduction of foreign DNA from another species. Transgenic animals, by contrast, carry an exogenous piece of DNA that is typically integrated randomly into the genome. Some transgenic constructs are designed to express a foreign protein, while others are designed to overexpress or misexpress an endogenous gene.
Historical Milestones
The field of transgenic animal technology emerged in the late 1970s and early 1980s. The first transgenic mice were produced in 1980 by Jon Gordon and Frank Ruddle, who used DNA microinjection into the pronucleus of fertilized mouse eggs. In 1982, Richard Palmiter and Ralph Brinster created the famous "supermouse" by injecting a fusion gene consisting of the mouse metallothionein promoter linked to the rat growth hormone gene. These mice grew significantly larger than their littermates, demonstrating that foreign genes could be expressed in mammals and produce phenotypic effects.
The development of embryonic stem (ES) cell technology in the 1980s, pioneered by Martin Evans, Matthew Kaufman, and Gail Martin, enabled gene targeting in mice. By 1989, Mario Capecchi and Oliver Smithies had independently developed methods for homologous recombination in ES cells, allowing precise gene modification. This technology earned them the Nobel Prize in Physiology or Medicine in 2007, shared with Martin Evans. The first transgenic livestock—sheep and pigs—were produced in 1985 using DNA microinjection. Since then, the field has expanded to include rabbits, goats, cattle, chickens, fish, and non-human primates, with increasingly sophisticated genetic tools.
Methods for Creating Transgenic Animals
Three principal methods have historically been used to create transgenic animals: DNA microinjection, retroviral vector-mediated gene transfer, and embryonic stem cell-mediated gene targeting. Each method has distinct advantages, limitations, and applications.
DNA Microinjection
DNA microinjection, also called pronuclear injection, is the most widely used method for producing transgenic mice and the primary method for transgenic livestock. The procedure involves the following steps:
- Superovulation and egg collection: Female donor animals are treated with hormones (pregnant mare serum gonadotropin followed by human chorionic gonadotropin) to induce superovulation. Fertilized eggs are collected from the oviducts.
- Pronuclear injection: Using a micromanipulator and a fine glass needle (approximately 1–2 µm diameter), a solution containing the transgene construct is injected directly into the larger of the two pronuclei of a fertilized egg. The DNA concentration is typically 1–5 ng/µL in a buffer such as 10 mM Tris-HCl (pH 7.4) with 0.1 mM EDTA. The injected volume is approximately 1–2 picoliters.
- Embryo transfer: Surviving injected eggs are surgically transferred into the oviducts of pseudopregnant recipient females, which have been mated with vasectomized males to induce a hormonal state receptive to pregnancy.
- Screening: Offspring are screened for transgene integration using polymerase chain reaction (PCR) or Southern blot analysis of genomic DNA extracted from tail or ear biopsies.
The transgene integrates randomly, typically as a concatemer (multiple copies arranged head-to-tail) at a single chromosomal site. Integration occurs after DNA replication, so the resulting animal is often a mosaic—only some cells carry the transgene. Breeding of founder animals is required to establish lines in which the transgene is present in the germline.
The success rate for microinjection is low: approximately 10–30% of mice born carry the transgene, and the rate is even lower in livestock species. The method requires significant technical skill and specialized equipment, but it remains the method of choice for many applications because it can accommodate large DNA constructs (up to several hundred kilobases) and does not require prior manipulation of embryonic stem cells.
Retroviral Vector-Mediated Transfer
Retroviral vectors were among the earliest tools for creating transgenic animals. This method exploits the natural ability of retroviruses to integrate their genetic material into the host genome. The approach involves:
- Vector construction: The transgene of interest is inserted into a replication-defective retroviral vector, typically derived from murine leukemia virus (MuLV) or lentiviruses such as HIV-1. The viral genes required for replication are removed and replaced with the transgene, while the cis-acting sequences necessary for packaging, reverse transcription, and integration are retained.
- Virus production: The vector is transfected into a packaging cell line that supplies the viral structural proteins in trans. The resulting viral particles are infectious but replication-incompetent—they can infect target cells but cannot produce new virus.
- Infection of embryos: The viral particles are introduced into embryos at various stages. For mice, this is often done by injecting the virus into the perivitelline space of zygotes or by co-culturing zona pellucida-free embryos with virus-producing cells. For larger animals, the virus can be injected into the blastocoel cavity of blastocyst-stage embryos.
- Embryo transfer and screening: Infected embryos are transferred to recipient females, and offspring are screened for transgene integration.
The key advantage of retroviral vectors is their high efficiency of integration—approaching 100% of infected embryos will carry at least one copy of the transgene. However, there are significant limitations. The transgene insert size is limited to approximately 8–10 kilobases for standard retroviral vectors (lentiviral vectors can accommodate slightly larger inserts). Integration is random and can disrupt endogenous genes, potentially causing insertional mutagenesis. Additionally, retroviral vectors are subject to transgene silencing due to DNA methylation and histone modifications at the integration site, particularly in the germline.
Lentiviral vectors, derived from HIV-1, have largely replaced MuLV-based vectors because they can transduce non-dividing cells, making them suitable for infecting early embryos and even oocytes. Lentiviral transduction has been used successfully to create transgenic rats, pigs, and other species where ES cell technology is not available.
Embryonic Stem Cell-Mediated Gene Targeting
Embryonic stem (ES) cell-mediated gene targeting is the most precise method for creating transgenic animals, but it is currently only practical in mice. ES cells are pluripotent cells derived from the inner cell mass of blastocyst-stage embryos. They can be maintained indefinitely in culture under appropriate conditions—typically on a feeder layer of mitotically inactivated mouse embryonic fibroblasts in medium supplemented with leukemia inhibitory factor (LIF) at 1000 U/mL.
The procedure involves:
- Gene targeting in ES cells: A targeting vector is constructed containing the transgene flanked by sequences homologous to the target locus. The vector is introduced into ES cells by electroporation. Through homologous recombination, the transgene is inserted at the desired chromosomal location. This occurs at a frequency of approximately 1 in 10⁶ to 10⁷ cells, so selection markers are essential. Typically, a positive selection marker (e.g., neomycin resistance) is included within the targeting construct, and a negative selection marker (e.g., thymidine kinase) is placed outside the homology arms to select against random integration.
- Selection and screening: ES cells are cultured in medium containing G418 (geneticin) at 200–400 µg/mL to select for cells that have integrated the construct. Cells that have undergone random integration are eliminated by treatment with ganciclovir, which is toxic to cells expressing thymidine kinase. Surviving clones are screened by Southern blot or long-range PCR to confirm correct targeting.
- Blastocyst injection: Correctly targeted ES cells are injected into the blastocoel cavity of host blastocysts using a micromanipulator. The injected blastocysts are transferred to pseudopregnant females.
- Chimera production and breeding: The resulting offspring are chimeras—animals composed of cells derived from both the host blastocyst and the injected ES cells. Chimerism is often assessed by coat color (e.g., agouti ES cells injected into black-coated host blastocysts). Male chimeras are bred to wild-type females, and offspring carrying the transgene are identified by PCR or Southern blot. Germline transmission is confirmed when the transgene appears in the offspring.
This method allows for precise control over the genetic modification, including the ability to create conditional knockouts using the Cre-loxP system, where the transgene is activated or inactivated in specific tissues or at specific times. The main limitation is that germline-competent ES cells are only reliably available for mice, although significant efforts are underway to establish such cells for rats and other species.
How Transgenic Animals Are Used in Research
Gene Function Studies
Transgenic animals are powerful tools for elucidating gene function. By overexpressing a gene of interest, researchers can observe the phenotypic consequences of increased gene dosage. Conversely, by expressing a dominant-negative mutant or an antisense RNA, researchers can effectively reduce gene function in a tissue-specific manner.
A classic approach involves the use of tissue-specific promoters to drive transgene expression. For example, the mouse mammary tumor virus (MMTV) promoter directs expression to the mammary gland, while the albumin promoter directs expression to the liver. The tetracycline-inducible system (Tet-On/Tet-Off) allows temporal control of transgene expression: the transgene is fused to a tetracycline-responsive element, and expression is activated or repressed by administration of doxycycline in the drinking water (typically 2 mg/mL) or in the diet.
Transgenic reporter animals, such as those expressing green fluorescent protein (GFP) under the control of a specific promoter, allow visualization of gene expression patterns in living tissues. These animals are invaluable for lineage tracing, where the progeny of specific cells are tracked during development or disease progression.
Disease Models
Transgenic animals, particularly mice, are widely used to model human diseases. The ability to introduce human disease-associated mutations into the mouse genome has revolutionized biomedical research.
For example, transgenic mice expressing the human amyloid precursor protein (APP) with familial Alzheimer's disease mutations (such as the Swedish mutation, K670N/M671L) develop amyloid plaques and cognitive deficits, providing a model for testing therapeutic interventions. Similarly, transgenic mice expressing the human huntingtin gene with expanded CAG repeats (greater than 40 repeats) recapitulate many features of Huntington's disease, including motor dysfunction and neuronal inclusions.
Transgenic mice carrying human oncogenes or tumor suppressor mutations have been instrumental in cancer research. The MMTV-PyMT (polyoma middle T antigen) mouse model develops mammary tumors with a predictable time course, while the K-ras⁺/⁻ (LSL-K-rasG12D) mouse model, when activated by Cre recombinase, develops lung adenocarcinomas. These models allow researchers to study tumor initiation, progression, and metastasis in a controlled genetic background.
Transgenic rats are increasingly used for modeling complex diseases such as hypertension, diabetes, and neuropsychiatric disorders, where their larger size and physiological differences from mice are advantageous. Transgenic rabbits have been used to model familial hypercholesterolemia and atherosclerosis, as their lipoprotein metabolism more closely resembles that of humans.
Biopharmaceutical Production
Transgenic animals can serve as "bioreactors" for the production of recombinant therapeutic proteins. The strategy involves directing transgene expression to the mammary gland using milk-specific promoters, such as the beta-lactoglobulin promoter or the casein promoter. The protein of interest is secreted into the milk, from which it can be purified.
This approach has several advantages over traditional cell culture-based production systems. The yield of recombinant protein in milk can be very high—up to several grams per liter. The post-translational modifications, particularly glycosylation, are more similar to human proteins than those produced in bacterial or yeast systems. The cost of production is lower than large-scale mammalian cell culture, particularly for proteins required in large quantities.
Several transgenic animals have been developed for this purpose. Transgenic goats expressing human antithrombin III in their milk were the first transgenic animals to produce an approved pharmaceutical product (ATryn, approved by the European Medicines Agency in 2006 and the US Food and Drug Administration in 2009). Transgenic rabbits expressing human C1 esterase inhibitor have also been developed. The production of monoclonal antibodies, blood clotting factors, and other therapeutic proteins in transgenic livestock continues to be an active area of research.
Examples of Transgenic Animals
Transgenic Mice
Transgenic mice are by far the most common and versatile transgenic animals. Their small size, short generation time (approximately 10 weeks), and well-characterized genetics make them ideal for research. The availability of germline-competent ES cells enables precise gene targeting, and the extensive toolkit of promoters, reporters, and recombinase systems allows sophisticated experimental designs.
The Transgenic Mice resource provides detailed protocols for generating and maintaining transgenic mouse lines. Key considerations include the choice of genetic background (e.g., C57BL/6, FVB/N, 129/Sv), which can influence phenotype, and the need for careful colony management to avoid genetic drift.
Transgenic mice have been created to model virtually every major human disease, including cancer, cardiovascular disease, diabetes, neurodegenerative disorders, and infectious diseases. They are also used to study developmental biology, immunology, and toxicology. The ability to create conditional and inducible transgenic systems has greatly expanded their utility.
Transgenic Rabbits and Goats
Transgenic rabbits are valuable for studying human diseases that are not well modeled in mice. Their larger size allows repeated blood sampling and surgical manipulation. Transgenic rabbits expressing human apolipoprotein(a) have been used to study lipoprotein(a) metabolism and its role in cardiovascular disease. The Watanabe heritable hyperlipidemic rabbit, though not transgenic in the strict sense, has been used extensively as a model of familial hypercholesterolemia.
Transgenic goats are primarily used for biopharmaceutical production. The first transgenic goat, named GF-1, was produced in 1991 by Genzyme Transgenics Corporation. GF-1 carried a transgene encoding human tissue plasminogen activator (tPA) under the control of the goat beta-casein promoter, and the protein was expressed in her milk. Subsequent generations of transgenic goats have produced antithrombin III, alpha-1-antitrypsin, and other therapeutic proteins.
The production of transgenic goats involves microinjection of the transgene into fertilized eggs, followed by embryo transfer into recipient does. The generation time for goats is approximately 5 months, and the time from transgene construction to production of a lactating founder female is typically 2–3 years.
Transgenic Pigs
Transgenic pigs have been developed for several purposes, including xenotransplantation, agricultural improvement, and disease modeling. The most significant application is xenotransplantation—the transplantation of pig organs into humans. Pigs are considered suitable organ donors due to their anatomical and physiological similarity to humans, but the major barrier is hyperacute rejection caused by the presence of galactose-α-1,3-galactose (α-Gal) epitopes on pig cell surfaces.
To address this, transgenic pigs have been created that express human complement regulatory proteins, such as human decay-accelerating factor (hDAF, CD55) or human membrane cofactor protein (hMCP, CD46), which inhibit complement-mediated lysis of pig cells by human antibodies. More recently, pigs with knockout of the α-1,3-galactosyltransferase (GGTA1) gene, combined with expression of multiple human transgenes, have been produced using CRISPR/Cas9 technology. These modifications have significantly prolonged the survival of pig organs in non-human primate models.
Transgenic pigs have also been created to produce human hemoglobin in their blood, human collagen in their tissues, and to serve as models for cystic fibrosis (by introducing the ΔF508 mutation in the CFTR gene) and retinitis pigmentosa. The generation time for pigs is approximately 1 year, and the production of transgenic pigs requires considerable resources, making them less accessible than mice for most research applications.
Advantages and Limitations of Transgenic Animals
Advantages
Transgenic animals offer several unique advantages over other experimental systems:
- Whole-organism context: Transgenic animals allow the study of gene function in the context of a complete, developing organism, including complex interactions between tissues and organ systems that cannot be replicated in cell culture.
- Heritable modifications: The transgene is passed to offspring, allowing the establishment of stable lines that can be maintained and expanded indefinitely.
- Temporal and spatial control: Advanced systems such as Cre-loxP and Tet-On/Tet-Off allow precise control over when and where the transgene is expressed.
- Human disease modeling: Transgenic animals carrying human genes or mutations provide physiologically relevant models for drug development and toxicity testing.
- Production of therapeutic proteins: Transgenic livestock can produce large quantities of recombinant proteins at lower cost than cell culture systems.
- Agricultural improvement: Transgenic animals with enhanced growth rates, disease resistance, or improved milk composition have potential agricultural applications.
Limitations
The limitations of transgenic animal technology are substantial:
- Random integration: In microinjection and retroviral methods, the transgene integrates at random chromosomal locations, which can disrupt endogenous genes or result in position effects that alter transgene expression.
- Mosaicism: Founder animals produced by microinjection are often mosaic, meaning the transgene is not present in all cells. This complicates phenotypic analysis and requires breeding to establish germline transmission.
- Transgene silencing: The transgene may be silenced over generations due to DNA methylation and heterochromatin formation, particularly if it integrates into a transcriptionally inactive region.
- Low efficiency: The efficiency of producing transgenic animals is low, particularly in livestock species. Microinjection success rates are typically 1–5% in large animals, and the cost per founder animal is high.
- Long generation times: For livestock species, the time required to produce a homozygous transgenic line is measured in years, making experiments slow and expensive.
- Ethical concerns: The production of transgenic animals raises animal welfare concerns, and the regulatory approval process for transgenic food animals is complex and uncertain.
Ethical and Regulatory Considerations
Animal Welfare
The creation of transgenic animals involves procedures that can cause pain, distress, or harm to the animals. Superovulation, surgical embryo transfer, and tissue biopsy for genotyping are invasive procedures. Some transgenes cause disease phenotypes, such as tumor development or neurodegeneration, which can result in significant suffering. The welfare of transgenic animals must be carefully considered, and experiments should be designed to minimize suffering.
The "3Rs" principle—Replacement, Reduction, Refinement—is central to ethical animal research. Replacement involves using alternative methods where possible, such as cell culture or computer modeling. Reduction involves using the minimum number of animals necessary to achieve statistically valid results. Refinement involves modifying procedures to minimize pain and distress, such as using anesthesia during surgery and providing appropriate analgesia post-operatively.
Institutional Animal Care and Use Committees (IACUCs) review all animal protocols to ensure they comply with ethical standards and regulatory requirements. The generation of transgenic animals requires specific approval, and the housing and breeding of these animals must meet established standards for environmental enrichment, social housing, and veterinary care.
Regulatory Frameworks
The regulation of transgenic animals varies by country and by intended use. In the United States, the Food and Drug Administration (FDA) regulates genetically engineered animals under the "new animal drug" provisions of the Federal Food, Drug, and Cosmetic Act. The FDA evaluates the safety and effectiveness of the genetic modification, including the stability of the transgene, the potential for environmental impact, and the safety of food products derived from the animals.
The European Union has a more restrictive framework. Directive 2001/18/EC governs the deliberate release of genetically modified organisms (GMOs), including transgenic animals, and requires a case-by-case environmental risk assessment. The European Medicines Agency (EMA) regulates the use of transgenic animals for pharmaceutical production.
Patenting of transgenic animals is a contentious issue. The first patent for a transgenic animal was granted in 1988 for the "Harvard mouse" (OncoMouse), which carries an activated oncogene and develops cancer. Patent protection allows the commercial exploitation of transgenic animal technology but raises concerns about the commodification of living organisms and the restriction of research access.
Common Pitfalls and Troubleshooting in Transgenic Animal Production
Mosaicism
Mosaicism is a common problem in transgenic animals produced by DNA microinjection. Because the transgene integrates after the first round of DNA replication, the founder animal contains a mixture of cells, some with and some without the transgene. If the transgene is not present in the germline, it will not be transmitted to offspring, and the founder is useless for establishing a line.
Troubleshooting: To maximize the chance of germline transmission, it is advisable to inject DNA into the pronucleus as early as possible after fertilization, before DNA replication begins. Screening a larger number of founder animals increases the probability of obtaining germline transmission. For ES cell-mediated targeting, mosaicism is less of an issue because the ES cells are selected and characterized before injection, but chimeras may still vary in the proportion of ES cell-derived tissues.
Transgene Silencing
Transgene silencing occurs when the integrated transgene is progressively inactivated over generations. This is often due to DNA methylation of CpG islands in the promoter region and the formation of repressive chromatin structures. Silencing is more likely when the transgene integrates into a heterochromatic region or when multiple copies are arranged in tandem.
Troubleshooting: The use of insulator elements, such as the chicken beta-globin insulator (cHS4), can protect the transgene from position effects. Including a matrix attachment region (MAR) in the construct can also help maintain an open chromatin structure. Selecting founder lines with single-copy integration events may reduce silencing. For long-term experiments, it is advisable to periodically verify transgene expression levels and to maintain lines as cryopreserved embryos or sperm to avoid genetic drift. Cryopreservation of Animal Cells is a valuable tool for preserving transgenic lines.
Off-Target Effects
Off-target effects are a concern with all methods of transgene integration, but they are particularly relevant for CRISPR/Cas9-mediated gene editing. The Cas9 nuclease can cleave at sites that are partially homologous to the guide RNA sequence, causing unintended mutations at other genomic locations. These off-target mutations can confound experimental results and have unintended phenotypic consequences.
Troubleshooting: The choice of guide RNA is critical. Guide RNAs with high specificity scores should be selected, and potential off-target sites should be identified using computational tools such as Cas-OFFinder or CRISPOR. The use of high-fidelity Cas9 variants, such as eSpCas9 or SpCas9-HF1, can reduce off-target cleavage. For transgenic animals produced by microinjection or ES cell targeting, whole-genome sequencing of founder animals can identify off-target mutations, and backcrossing to wild-type animals can eliminate unwanted mutations.
Additional Common Issues
Low pregnancy rates after embryo transfer: This can result from poor embryo quality, suboptimal transfer technique, or inadequate recipient preparation. Ensuring proper hormonal synchronization of recipients and minimizing the time embryos spend outside the incubator can improve success.
Failure of germline transmission: If chimeric mice do not transmit the ES cell-derived genome, this may be due to a low contribution of ES cells to the germline. Using ES cells from a different mouse strain than the host blastocyst (e.g., 129/Sv ES cells into C57BL/6 blastocysts) and selecting male chimeras with high coat color contribution can improve the odds.
Transgene expression in unexpected tissues: The promoter used to drive transgene expression may have broader specificity than expected. This can be addressed by using well-characterized promoters and by including additional regulatory elements, such as enhancers or locus control regions, to restrict expression.
Contamination of cell cultures: When working with ES cells or other cultured cells used in transgenic production, contamination with mycoplasma can compromise cell viability and differentiation potential. Regular Mycoplasma Testing is essential. Proper Cell Passaging techniques and Animal Cell Culture practices should be followed to maintain cell health. Calculate Cell Viability before injection or electroporation to ensure that cells are healthy and will survive the procedure.
Summary and Future Directions
Future Prospects
The advent of CRISPR/Cas9 technology has revolutionized the field of transgenic animal production. Unlike traditional methods, CRISPR/Cas9 allows targeted modification of the genome with unprecedented ease and efficiency. The system consists of two components: the Cas9 nuclease and a single-guide RNA (sgRNA) that directs Cas9 to a specific genomic sequence. The Cas9-sgRNA complex introduces a double-strand break at the target site, which is then repaired by either non-homologous end joining (NHEJ), resulting in small insertions or deletions (indels), or homology-directed repair (HDR), which can introduce precise modifications when a donor template is provided.
CRISPR/Cas9 has several advantages over traditional transgenic methods:
- Efficiency: The efficiency of CRISPR-mediated gene editing is much higher than homologous recombination in ES cells, and it works in a wide range of species, including rats, pigs, rabbits, and non-human primates.
- Multiplexing: Multiple genes can be targeted simultaneously by providing multiple sgRNAs, allowing the creation of animals with complex genetic modifications in a single step.
- Conditional editing: The use of inducible Cas9 systems (e.g., Cre-dependent Cas9 expression) allows temporal control of gene editing.
- Reduced cost and time: The generation of gene-edited animals is faster and less expensive than traditional transgenic methods, making the technology accessible to a broader range of laboratories.
Base editing, a derivative of CRISPR technology, allows the conversion of one DNA base to another without introducing a double-strand break. This enables the introduction of point mutations with high precision and minimal off-target effects. Prime editing, another recent advance, allows the insertion or deletion of small DNA sequences and the correction of point mutations.
The future of transgenic animal technology will likely involve the combination of these advanced tools with a broader range of species. The establishment of germline-competent ES cells for rats, pigs, and other livestock species would enable precise gene targeting in these animals. The development of inducible and cell-type-specific gene editing systems will allow more sophisticated experimental designs.
The use of transgenic animals in agriculture is also likely to expand. Gene-edited livestock with enhanced disease resistance, improved feed efficiency, or reduced environmental impact are under development. The approval of gene-edited animals for food production, such as the fast-growing AquAdvantage salmon (approved in Canada and the United States), signals a shift toward the commercialization of genetically modified animals.
The ethical and regulatory landscape will continue to evolve as the technology advances. The distinction between transgenic animals (carrying foreign DNA) and gene-edited animals (with modifications to endogenous genes) is likely to become increasingly important, as some regulatory frameworks treat these categories differently. Public engagement and transparent communication about the benefits and risks of transgenic animal technology will be essential for its responsible development and application.
Frequently Asked Questions
What are transgenic animals?
Transgenic animals are animals whose genomes have been deliberately modified by the introduction of foreign DNA sequences. The introduced transgene is stably integrated into the germline and is inherited by subsequent generations. Transgenic animals are created using methods such as DNA microinjection, retroviral vector-mediated gene transfer, or embryonic stem cell-mediated gene targeting.
What is a transgenic animal?
A transgenic animal is an animal that carries a foreign gene (transgene) that has been deliberately inserted into its genome. The transgene can come from the same species, a different species, or be a synthetic construct. The key feature is that the genetic modification is heritable and present in the germline.
What are examples of transgenic animals?
Examples of transgenic animals include:
- Transgenic mice expressing human growth hormone (the "supermouse")
- Transgenic mice carrying human APP mutations for Alzheimer's disease research
- Transgenic goats producing human antithrombin III in their milk
- Transgenic pigs expressing human complement regulatory proteins for xenotransplantation
- Transgenic rabbits expressing human apolipoprotein(a) for cardiovascular research
- Transgenic mice expressing GFP under tissue-specific promoters for lineage tracing
Why are transgenic animals used?
Transgenic animals are used for several purposes:
- To study gene function in a whole-organism context
- To model human diseases, including cancer, neurodegenerative disorders, and cardiovascular disease
- To produce recombinant therapeutic proteins in milk or other body fluids
- To improve agricultural traits, such as growth rate and disease resistance
- To study developmental biology and gene regulation
What is the purpose of transgenic animals?
The purpose of transgenic animals is to introduce a specific genetic modification into an animal to study the function of a gene, model a human disease, produce a therapeutic protein, or improve an agricultural trait. The ability to control the genetic makeup of an animal allows researchers to ask precise questions about gene function and to create animal models that recapitulate human diseases.
What are the advantages of transgenic animals?
The advantages of transgenic animals include:
- The ability to study gene function in the context of a complete organism
- The creation of heritable genetic modifications that can be maintained as stable lines
- The production of physiologically relevant disease models for drug development
- The production of recombinant therapeutic proteins at scale
- The potential for agricultural improvement through enhanced growth, disease resistance, or product quality
Key Takeaways
- Transgenic animals carry a foreign gene (transgene) stably integrated into their germline, distinguishing them from knockout or knock-in animals that modify endogenous genes.
- The three principal methods for creating transgenic animals are DNA microinjection, retroviral vector-mediated gene transfer, and embryonic stem cell-mediated gene targeting, each with distinct efficiencies, insert size limits, and precision.
- Transgenic mice are the most versatile and widely used transgenic animals, while transgenic rabbits, goats, and pigs serve specialized roles in disease modeling, biopharmaceutical production, and xenotransplantation.
- Transgenic animals are used to study gene function, model human diseases, and produce recombinant therapeutic proteins, with applications spanning basic research, drug development, and agriculture.
- Major limitations include random transgene integration, mosaicism, transgene silencing, low efficiency in livestock, and long generation times, which can be mitigated through careful experimental design and the use of advanced technologies.
- CRISPR/Cas9 and related technologies are transforming the field by enabling precise, efficient, and multiplexed genome editing in a broader range of species.
- Ethical and regulatory considerations, including animal welfare, patenting, and food safety, are integral to the responsible development and application of transgenic animal technology.
Further Reading
- Tsika RW. Transgenic animal models. Exercise and sport sciences reviews. 1994. PubMed 7925549
- Whitelaw B. Transgenic animal welfare. Transgenic research. 2001. PubMed 11708648
- Murray JD et al. Ten transgenic animal research conferences and counting. Transgenic research. 2016. PubMed 26858236
- Wall RJ et al. Transgenic animal technology. Journal of andrology. 1997. PubMed 9203049
- Shakweer WME et al. A review of transgenic animal techniques and their applications. Journal, genetic engineering & biotechnology. 2023. PubMed 37160523
- Lee VM, Kenyon TK, Trojanowski JQ. Transgenic animal models of tauopathies. Biochimica et biophysica acta. 2005. PubMed 15615643